![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Melinta Therapeutics Inc | NASDAQ:MLNT | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.50 | 0.51 | 0.5198 | 0 | 01:00:00 |
|
|
|
|
|
DELAWARE
|
|
001-35405
|
|
45-4440364
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
44 Whippany Road, Morristown, NJ
|
|
07960
|
(Address of principal executive offices)
|
|
(Zip Code)
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading
Symbols(s) |
Name of each exchange of which registered
|
Common Stock, $0.001 Par Value
|
MLNT
|
Nasdaq Global Market
|
Item 5.07.
|
Submission of Matters to a Vote of Security Holders.
|
1.
|
The Company’s stockholders voted to elect the following three Class II members to our board of directors, each for a three-year term expiring at the annual meeting of stockholders in 2022:
|
|
|
|
|
|
|
|
Members
|
|
Number of Shares Voted For
|
|
Number of Shares Voted Against or
Abstained
|
|
Broker Non-Votes
|
Jay Galeota
|
|
5,365,180
|
|
900,752
|
|
3,360,028
|
Thomas P. Koestler, M.D.
|
|
4,455,441
|
|
1,810,491
|
|
3,360,028
|
David Zaccardelli, Pharm. D.
|
|
5,102,874
|
|
1,163,058
|
|
3,360,028
|
2.
|
The Company’s stockholders approved, on a non-binding advisory basis, Melinta’s 2018 executive compensation. The vote for such approval was 5,283,937 shares for, 970,978 shares against, 11,017 shares abstaining, and 3,360,028 shares of broker non-votes.
|
3.
|
The Company’s stockholders ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2019. The vote for such ratification was 8,602,270 shares for, 954,676 shares against, 69,014 shares abstaining and no broker non-votes.
|
|
|
|
|
|
Date: June 10, 2019
|
|
Melinta Therapeutics, Inc.
|
||
|
|
|
||
|
|
By:
|
|
/s/ Peter J. Milligan
|
|
|
|
|
Peter J. Milligan
|
|
|
|
|
Chief Financial Officer
|
1 Year Melinta Therapeutics Chart |
1 Month Melinta Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions